1. Cyklis R, Armata J, Dluzniewska A, Boguslawska-Jaworska J, Pejcz J, Wolak D et al. The results of therapy of the acute myeloblastic leukemia in childhood with AML-BFM-83 regimen in the material of the Polish Group on Therapy of Leukemia in Childhood Preliminary report. Pol Tyg Lek 1988; 43: 376–379.
2. Cyklis R, Dluzniewska A, Armata J, Boguslawska -Jaworska J, Ochocka M, Januszkiewicz-Lewandowska D et al. Efficacy of AML-BFM-83 regimen in children with acute myeloblastic leukemia. Over 10 year experience of Polish Pediatric Leukemia/Lymphoma Study Group. Acta Hematol Pol 1996; 27: 131–137.
3. Dluzniewska A, Balwierz W, Moryl-Bujakowska A, Boguslawska-Jaworska J, Dobaczewski G, Januszkiewicz-Lewandowska D et al. Intermediate doses of cytarabine arabinoside in the treatment of acute non- lymphoblastic leukemia in children. Medycyna Wieku Rozwojowego 2000; 4 (Suppl 2): 33–41.
4. Dluzniewska A, Balwierz W, Balcerska A, Chybicka A, Dobaczewski G, Kowalczyk J et al. Efficacy of idarubicin in the treatment of childhood acute non lymphoblastic leukemia – report of Polish Pediatric Leukemia/Lymphoma Study Group. Przegl Lek 2003; 60 (Suppl 5): 17–21.
5. Creutzig U, Ritter J, Schellong G . Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990; 75: 1932–1940.